Antibody ID	ANTI0TBJIE
Antibody Name	Her2-PT-H16-K222R-hG1
Synonyms	Her2-PT-H16-K222R-hG1    Click to Show/Hide
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.63 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.48 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.71 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	122 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5849 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.13 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.82 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.42 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.15 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.21 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	704 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.14 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.84 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.29 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.74 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.27 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	637 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.23 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.48 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.83 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.69 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.1 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	932 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 1.52 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.52 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.64 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Ref 1	Calicheamicin derivatives and antibody drug conjugates thereof